Wallerian degeneration is delayed when sufficient levels of
proteins with NMNAT activity are maintained within axons after injury. This has been proposed to form the basis of 'slow
Wallerian degeneration' (Wld (S)), a neuroprotective phenotype conferred by an aberrant fusion
protein, Wld(S).
Proteasome inhibition also delays
Wallerian degeneration, although much less robustly, with stabilization of NMNAT2 likely to play a key role in this mechanism. The pan-
MEK inhibitor
U0126 has previously been shown to reverse the axon-protective effects of
proteasome inhibition, suggesting that
MEK-ERK signaling plays a role in delayed
Wallerian degeneration, in addition to its established role in promoting neuronal survival. Here we show that whilst
U0126 can also reverse Wld(S)-mediated axon protection, more specific inhibitors of MEK1/2 and MEK5,
PD184352 and
BIX02189, have no significant effect on the delay to
Wallerian degeneration in either situation, whether used alone or in combination. This suggests that an off-target effect of
U0126 is responsible for reversion of the axon protective effects of Wld(S) expression or
proteasome inhibition, rather than inhibition of MEK1/2-ERK1/2 or MEK5-ERK5 signaling. Importantly, this off-target effect does not appear to result in alterations in the stabilities of either Wld(S) or NMNAT2.